Analyst Research

Report Title Price
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: Pechala's Reports
$15.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Novo Nordisk A/S's Ryzodeg Passes Review by First Committee on Drugs of Japan’s Pharmaceutical Affairs


Monday, 3 Dec 2012 01:40am EST 

Novo Nordisk A/S announced that Ryzodeg (insulin degludec/insulin aspart) has passed the review by the First Committee on Drugs of Japan’s Pharmaceutical Affairs. The remaining step in the regulatory process is an approval from the Ministry of Health, Labor and Welfare. The First Committee on Drugs of Pharmaceutical Affairs serves as an advisory body to the Ministry in matters related to pharmaceuticals including new drug applications. Novo Nordisk expects to receive marketing authorization from the Ministry within a few months. 

Company Quote

45.43
0.03 +0.07%
10 Jul 2014